Form 4: Helius Medical Technologies CMO Granted 17,500 Stock Options

Helius Medical Technologies, Inc. Chief Medical Officer Antonella R. Favit-Van Pelt was granted 17,500 stock options with an exercise price of $9.76 per share.

Summary

• Antonella R. Favit-Van Pelt, the Chief Medical Officer of Helius Medical Technologies, Inc. (HSDT), was granted 17,500 stock options.
• The stock options have an exercise price of $9.76 per share.
• The transaction date for this grant was July 2, 2025.
• The options were granted under the Issuer's 2022 Equity Incentive Plan.
• 50% of the granted options vested immediately upon grant.
• The remaining 50% of the options will vest in twelve successive equal quarterly installments, beginning on September 30, 2025.
• Vesting is contingent upon Ms. Favit-Van Pelt's continued service through each applicable vesting period.
• The expiration date for these stock options is July 1, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects a standard executive compensation practice that aligns management's interests with shareholders, indicating stability and retention of key personnel. It is not highly positive as it's a routine disclosure rather than a significant new development.

Positives

• The grant of stock options to the Chief Medical Officer aligns her interests with those of the shareholders, incentivizing long-term performance and value creation.
• This action is a standard practice for executive compensation, aiding in the retention of key personnel.

Future Outlook

The vesting schedule for the stock options, extending through quarterly installments until September 30, 2025, and beyond, indicates an expectation of continued service from the Chief Medical Officer, aligning her long-term commitment with the company's future performance.

Industry Context

The grant of stock options to a Chief Medical Officer is a common practice in the medical technology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and incentivize top talent by linking their financial success to the company's stock performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation across various industries, including medical technology, designed to align executive interests with shareholder value.
• Specific benchmarks for Helius Medical Technologies' peer group or the size of this particular grant relative to industry averages for Chief Medical Officers are not provided within this filing.

Corporate Governance

Related Party Transactions

• The grant of stock options to Antonella R. Favit-Van Pelt, the Chief Medical Officer, constitutes a transaction between the company and a related party (an executive officer).

Stakeholder Impact

• Shareholders: The grant aims to align the Chief Medical Officer's financial incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: The compensation structure for key executives can influence overall employee morale and retention strategies, though this specific grant is for a single officer.

Next Steps

• Continued vesting of the remaining 50% of stock options in twelve equal quarterly installments, subject to the Chief Medical Officer's continued service.

Key Dates

Keywords

Helius Medical Technologies, HSDT, Stock Option, Executive Compensation, Insider Transaction, Form 4, Chief Medical Officer, Equity Incentive Plan